Skip to Content
Upcoming Webinar

Adverse Effects Associated with Bispecific T-Cell Engagers

Date: September 3, 2025 | 2:00 PM
Date: Wednesday, September 3, 2025
Time: 2 pm EST
Presenter: Nicholas Bitz, PharmD, MBA (University Hospital Cleveland Medical Center) &  C. Brooke Adams, Pharm.D., BCOP (Orlando Health Cancer Institute)

Bispecific T-cell engagers (BTCEs) represent an exciting advancement in cancer care — but with their promise comes the responsibility of managing a unique set of adverse effects. For providers, distinguishing between mild and severe reactions, understanding the mechanisms behind them, and responding quickly can make a meaningful difference in patient outcomes.

This CE-accredited session, led by Nicholas Bitz, PharmD, MBA (University Hospital Cleveland Medical Center) and C. Brooke Adams, PharmD, BCOP (Orlando Health Cancer Institute), offers practical guidance for oncology professionals navigating these challenges in real-world practice.

Participants will learn how to:

  • Recognize and describe common adverse effects associated with BTCE therapy.
  • Understand the pathophysiology driving these effects.
  • Differentiate between mild vs. severe reactions and determine appropriate interventions.
  • Assess patient symptoms effectively to identify early warning signs.
  • Apply standard operating procedures when managing patients experiencing adverse effects.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.